Publication: A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease
Issued Date
2008-02-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-40949135270
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.91, No.2 (2008), 196-202
Suggested Citation
Kritvikrom Durongpisitkul, Decho Jakrapanichakul, Suree Sompradikul A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Journal of the Medical Association of Thailand. Vol.91, No.2 (2008), 196-202. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19767
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease
Other Contributor(s)
Abstract
Background: Pulmonary Arterial Hypertension (PAH) plays a significant role in morbidity and mortality of patients with congenital heart disease (CHD). Bosentan, a dual endothelin receptor antagonist has been approved for PAH patients with Eisenmenger physiology (EP). The authors retrospectively reviewed the efficacy and safety of bosentan in Thai PAH patients associated with CHD. Material and Method: The study population was obtained from the databases of the CHD patients at Siriraj Hospital from October 2004 to April 2007 who received 6 months of bosentan treatment. Inclusion criteria are: CHD with Eisenmenger physiology (EP) or those with severe PAH after surgical repair or interventional cardiac catheterization. Clinical characteristics including the 6 - minute walk test (6MWT) distances, oxygen saturation (O2 sat), New York Heart Association (NYHA) functional class, and right ventricular systolic pressure (RVSP) at baseline were compared with those at 1, 3, and 6 months post bosentan treatment. Signs and symptoms of adverse events were also recorded. Results: There were 11 patients from among those who fitted the inclusion criteria and whose records were examined. Their average age was 51.1 ± 10.1 years old (13-61 years old). Patients were divided into 2 groups; Group A (6 patients) was PAH with EP and Group B (5 patients) was PAH post intervention. In group A, the 6MWT increased from 151 ± 69 meters to 293 ± 61 meters (p = 0.001) with the average increase of 38 ± 61 meters. The O2 sat increased from 83 ± 12.7% to 91.8 ± 5.6% (p = 0.038) with an average increase of 1.4 ± 0.07%. There was no significant change in right ventricular systolic pressure (RVSP). In group B, there was a trend in 6MWT improvement from 274 ± 69 meters to 312 ± 38 meters but this was not statistically different. There were improvements in the NYHA functional class in both groups. There was no significant increase in serum aminotransferase at the end of 6 months in each patient. Conclusion: There are benefits of bosentan for treatment of severe PAH in CHD, especially in patients with Eisenmenger physiology. Obvious benefits are an improvement of 6MWT and O2 sat.